Decision-Makers Agree—Phase I Clinical Research is Becoming More Complex

Informing pharmaceutical drug developers, manufacturers, and service providers Raleigh, N.C. — October 16, 2018 — Industry Standard Research (ISR) announces the release of its newest report, “Phase I Study Trends and Market Outlook (2018-2022),” in which 143 Phase I decision-makers provide valuable insight into market size, factors that could affect the number of studies conducted … Continued

Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations

Editor Anna Rose Welch at Biosimilar Development speaks to VP of Industry Standard Research Kate Hammeke about our recent report Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition). Indeed, there are already 11 percent of respondents currently selling biosimilars to their own biologic. And of the 41 percent of respondents who are currently considering biosimilars … Continued

ISR CUSTOMERS